Company: CWAN
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001193125-25-004935
Chunk: 1

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 7.01
Chunk 1
---
 limited to, the Company’s and Enfusion’s ability to successfully close the Mergers, the Company’s ability to successfully integrate the operations and technology of Enfusion with those of the Company, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion’s clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under “ Risk Factors” in the Company’s Annual Report on Form10-Kfor the year ended December 31, 2023 filed with the SEC on February 29, 2024, and in other periodic reports filed by the Company with the SEC, which are available on the Company’s website at https://investors. clearwateranalytics. com and on the website of the Securities and Exchange Commission at www. sec. gov. All forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company does not undertake any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

NO OFFER OR SOLICITATION

This report is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Additional Information and Where to Find It

In connection with the Mergers, the Company will file with the SEC a Registration Statement on Form S-4(the “ Registration Statement”) to register the shares of the Company’s common stock to be issued pursuant to the Mergers, which will include a prospectus of the Company and a proxy statement of Enfusion (the “proxy statement/prospectus”). Each of the Company and Enfusion